Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial

Lancet

Volumn 362, Issue 9377, 2003, Pages 7-13

  Poole Wilson, Philip A ^a,n   Swedberg, Karl ^b   Cleland, John G F ^c   Di Lenarda, Andrea ^d   Hanrath, Peter ^e   Komajda, Michel ^f   Lubsen, Jacobus ^g,h   Lutiger, Beatrix ⁱ   Metra, Marco ^j   Remme, Willem J ^k   Torp Pedersen, Christian ^l   Scherhag, Armin ⁱ   Skene, Allan ^m  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF HULL   (United Kingdom)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SOCAR RESEARCH SA   (Switzerland)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j UNIVERSITY OF BRESCIA   (Italy)

^k Sticares Cardiovascular Research Foundation   (Netherlands)

^l BISPEBJERG HOSPITAL   (Denmark)

^m Nottingham Clinical Research Group   (United Kingdom)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL TARTRATE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 3142776467     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13800-7     Document Type: Article

References (29)

1. Cowie M.R., Mosterd A., Wood D.A., et al. The epidemiology of heart failure. Eur Heart J. 18:1997;208-225.
2. Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560.
3. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: collaborative Group on ACE Inhibitor Trials. JAMA. 273:1995;1450-1456.
4. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007.
7. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
8. Shibata M.C., Flather M.D., Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail. 3:2001;351-357.
9. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 283:2000;1295-1302.
10. Bolger AP, Al-Nasser F. Beta-blockers for chronic heart fialure: surviving longer but feeling better? Int J Cardiol. Available from http://www.sciencedirect.com/science/jpurnal/01675273 (accessed June 10, 2003).
11. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 349:1997;375-380.
12. Gilbert E.M., Abraham W.T., Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 94:1996;2817-2825.
13. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:2001;1659-1667.
14. Packer M., Antonopoulos G.V., Berlin J.A., Chittams J., Konstam M.A., Udelson J.E. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 141:2001;899-907.
15. Di Lenarda A., Sabbadini G., Salvatore L., et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol. 33:1999;1926-1934.
16. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., Dei C.L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long- term effects of metoprolol versus carvedilol. Circulation. 102:2000;546-551.
17. Sanderson J.E., Chan S.K.W., Yip G., et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol. 34:1999;1522-1528.
18. Jacob S., Rett K., Wicklmayr M., Agrawal B., Augustin H.J., Dietze G.J. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 14:1996;489-494.
19. Yue T.L., Cheng H.Y., Lysko P.G., et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 263:1992;92-98.
20. Rossig L., Haendeler J., Mallat Z., et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 36:2000;2081-2089.
21. Poole-Wilson P.A., Cleland J.G., Di Lenarda A., et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail. 4:2002;321-329.
22. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 34:1976;585-612.
23. Lubsen J., Hoes A., Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet. 356:2000;1757-1759.
24. Freemantle N., Calvert M., Wood J., Eastaugh J., Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 289:2003;2554-2559.
25. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
26. Waagstein F., Bristow M.R., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
27. Sandberg A., Blomqvist I., Jonsson U.E., Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol. 33:(suppl):1988;S9-S14.
28. Wikstrand J., Hjalmarson A., Waagstein F., et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 40:2002;491-498.
29. Lechat P., Hulot J.S., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 103:2001;1428-1433.